The purpose of this study is to investigate the effect of using truncated area under the curve AUC) method on the bioequivalence of different drugs in healthy volunteers. Model drugs used clopidogrel, glimepiride, losartan, carvedilol, carbamazepine, diazepam, donepezil, tramadol and repaglinide. 24 -38 healthy subjects participated in each study using cross over design. Individual disposition kinetic parameters of areas under plasma concentrations (AUC 0-t , AUC 00 ), maximum concentration (C max ) and time to reach maximum concentration (T max ) were calculated by non-compartmental analysis using Kinetica program V 4.2 using all data points. In addition, truncated AUC was calculated up to median T max of reference product. No direct correlation was shown between study results due to AUC truncation. The 90 % confidence intervals for logtransformed AUC 0-t , AUC 00 , and C max were not always in agreement with the 90 % confidence intervals for log-transformed truncated AUC. More over, the 90 % confidence intervals for log-transformed AUC 0-t , AUC 00 passed in all drugs, while those for C max failed in 3 drugs and for truncated AUC failed in seven drugs. This indicates that C max , AUC 0-t , AUC 00 rather than truncated AUC are more accurate to determine formulation differences, which is the goal of bioequivalence studies. It was shown that intra-subject variability is usually higher in truncated AUC as compared to variabilities of AUC 0-t , AUC 00 , and Cmax. This rendered the sample size to be in adequate for calculation of tuncated AUC parameter, which explained the high failure rate in its limits. These results suggest not using truncated AUC to support the bioequivalence of drugs where rapid absorption is of importance as recommended by the draft EMEA guideline.
Introduction
Studies to measure bioavailability and/or establish bioequivalence of a product are important elements in support of the different drug applications and their supplements (1) . Of special interest are bioequivalence studies of drugs that require rapid absorption and onset of action. Hence, it was recommended by the new draft EMEA guideline that 90 % confidence intervals for log-transformed areas under curve (AUC 0-t , AUC 00 ), maximum plasma concentration (C max ) and partial AUC, truncated at median time to reach maximum concentration (T max ) of the reference product, to fall between 80-125 % (1).
The purpose of this study is to investigate the effect of using truncated area under the curve AUC method on the bioequivalence of high (intra-subject variability > 30%) and low (intra-subject variability < 30%) variable drugs that require rapid absorption and onset of action in healthy volunteers (1) . Model drugs used were clopidogrel, glimepiride, losartan, carvedilol, carbamazepine, diazepam, donepezil, tramadol and repaglinide. They were chosen based on clinical opinions about the need for rapid absorption and onset on action.
Materials and Methods

Drugs
Drug formulations were clopidogrel, glimepiride, losartan, carvedilol, carbamazepine, diazepam, donepezil, tramadol and repaglinide.
Subjects and Study Design
24 -36 healthy adult male volunteers participated in each of a two formulation, two sequence, two period cross-over single oral dose studies. Sample size for each study was calculated based on reported intra-subject variability of pharmacokinetics primary parameters, considering α = 0.05, the bioequivalence range (0.8-1.25) and to obtain a statistical power greater than 80%. All subjects had mean age, mean body weight and mean height. The volunteers were instructed to abstain from taking any drug including over-the counter (OTC) for 2 weeks prior to and during the study period. Studies were performed according to the revised Declaration of Helsinki for bio-medical research involving human subjects and the rules of Good Clinical Practices. Also, study protocols were approved by Institutional Review Board (IRB) of IPRC.
Experimental and Assay Procedure
In each study, following a ten-hour overnight fast, single oral dose of each drug was administered followed by 240-ml water in each study. Blood samples were collected up to 24 -240 hour after dosing. Samples were stored at -20 o C until analyzed by validated and sensitive hplc or LC-MS methods. 
Data Analysis
Analysis were done on parent drugs only not on metabolites. Areas under plasma concentrations (AUC 0-t , AUC 00 ), maximum concentration (C max ), time to reach maximum concentration (T max ) and truncated AUC were calculated by non-compartmental analysis for all subjects using Kinetica ® software (2). Confidence interval analysis for log-transformed AUC 0-t , AUC 00 , C max and partial AUC, truncated at median T max of the reference product were calculated using Kinetica ® software (2).
Results and Discussion
Confidence interval analysis results were summarized in Table  1 . Per the new draft EMEA guideline, the 90 % confidence intervals for log-transformed AUC 0-t , AUC 00 , C max and partial AUC, truncated at median T max of the reference product, are to fall between 80-125 % (1). In this research, we investigated the effect of using truncated area under the curve method on the bioequivalence of different drugs in healthy volunteers. T max is a good indicator of continued absorption of a drug from the GIT, though absorption may continue afterwards. However and as shown in table 1, T max variability was high in most drugs with confidence limits felled outside acceptance range. Yet, T max is secondary parameter and final bioequivalence conclusion is not based on T max .
As shown in table 1, the 90 % confidence intervals for logtransformed AUC 0-t , AUC 00 , and C max were not always in agreement with the 90 % confidence intervals for log-transformed truncated AUC. Intra-subject variability of primary original parameters were as expected, indicating adequate sample size. However, point estimates and confidence intervals of C max for the first 3 drugs indicated formulation differences. More over, the 90 % confidence intervals for log-transformed AUC 0-t , AUC 00 passed in all drugs, while those for Cmax failed in 3 drugs and for truncated AUC failed in seven drugs. This indicates that C max , AUC 0-t , AUC 00 rather than truncated AUC are more accurate to determine formulation differences, which is the goal of bioequivalence studies. It was shown that intra-subject variability is usually higher in truncated AUC as compared to variabilities of AUC 0-t , AUC 00 , and C max . This rendered the sample size to be in adequate for calculation of tuncated AUC parameter, which explained the high failure rate in its limits. Actually, truncated AUC parameter is not mandatory but only recommended according to US FDA guideline (3). These results suggest not using truncated AUC to support the bioequivalence of drugs where rapid absorption is of importance as recommended by the draft EMEA guideline.
Conclusion
C max , AUC 0-t , AUC 00 rather than truncated AUC are more ac- 
